On December 21, 2022, the New Zealand Medicinal Cannabis Agency announced the verification of two new medicinal cannabis products containing tetrahydrocannabinol (THC) that meet quality standards.
A week ago, Helius became New Zealand's first company to be GMP certified, allowing them to produce THC extracts and manufacture THC-containing medications.
Carmen Doran, CEO of Helius, stated, "We are delighted to bring more medicinal cannabis products grown and manufactured in New Zealand to patients in the country.
Helius will have a total of six drugs in its product portfolio in 2022, as two new drugs have entered the New Zealand market. This brings their total of new drugs to four.
In mid-December, we were able to announce GACP certification, and since then, we have also received GMP certification for four additional processes at our factory in the East Auckland area. This progress demonstrates the strength of the Helius team," she said.
Helius is the only company in New Zealand that has obtained Good Manufacturing Practice (GMP) certification for the extraction and production of CBD and THC medications. Even more importantly, it is one of only two companies in the country that currently has six products validated to meet the minimum quality standards (the other being Nubu Pharma).
Helius' latest product will be exported to European clients in 2023.
The products containing THC have attracted great interest internationally, and with the continued growth of the medical market, globally manufactured GMP products have received widespread attention. We have found that people are particularly interested in balanced full-spectrum medicinal cannabis formulas," said Ms. Doran.
With the launch of these products, New Zealand patients can now use a variety of locally manufactured oral liquid products. They no longer have to rely on imported products that may experience supply delays throughout 2022 and potentially be much more expensive.
The newly approved drug was developed at Helius' large manufacturing facility. Cannabinoids are active compounds found in the cannabis plant, which are also extracted from dried flowers grown at the Helius factory, allowing them to produce plant-based solutions for patients under one roof.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
